TD Asset Management Inc. Has $24.30 Million Stake in Zoetis Inc. (ZTS)
TD Asset Management Inc. lowered its position in Zoetis Inc. (NYSE:ZTS) by 57.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 389,511 shares of the company’s stock after selling 532,857 shares during the period. TD Asset Management Inc.’s holdings in Zoetis were worth $24,298,000 at the end of the most recent reporting period.
Other hedge funds also recently bought and sold shares of the company. Assetmark Inc. raised its stake in Zoetis by 4.6% in the first quarter. Assetmark Inc. now owns 1,918 shares of the company’s stock worth $102,000 after buying an additional 85 shares in the last quarter. Guardian Life Insurance Co. of America raised its stake in Zoetis by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 1,905 shares of the company’s stock worth $102,000 after buying an additional 13 shares in the last quarter. Point72 Asia Hong Kong Ltd bought a new stake in Zoetis during the first quarter worth $111,000. Advisory Services Network LLC bought a new stake in Zoetis during the first quarter worth $112,000. Finally, First Interstate Bank raised its stake in Zoetis by 3.5% in the first quarter. First Interstate Bank now owns 2,250 shares of the company’s stock worth $120,000 after buying an additional 76 shares in the last quarter. Institutional investors own 94.51% of the company’s stock.
Zoetis Inc. (NYSE:ZTS) opened at 59.73 on Friday. The firm has a market capitalization of $29.21 billion, a P/E ratio of 33.76 and a beta of 1.02. Zoetis Inc. has a 52-week low of $46.86 and a 52-week high of $63.85. The company has a 50 day moving average price of $62.20 and a 200 day moving average price of $58.00.
Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, August 8th. The company reported $0.53 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.53. The business had revenue of $1.27 billion during the quarter, compared to analysts’ expectations of $1.27 billion. Zoetis had a net margin of 17.50% and a return on equity of 62.49%. The company’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same period in the previous year, the company earned $0.49 EPS. On average, equities analysts forecast that Zoetis Inc. will post $2.34 EPS for the current fiscal year.
A number of analysts have weighed in on ZTS shares. Zacks Investment Research upgraded Zoetis from a “hold” rating to a “buy” rating and set a $67.00 target price for the company in a report on Wednesday, May 10th. Jefferies Group LLC upped their target price on Zoetis from $65.00 to $70.00 and gave the stock a “buy” rating in a report on Tuesday, May 9th. BMO Capital Markets restated a “buy” rating and set a $60.00 target price on shares of Zoetis in a report on Thursday, May 4th. Argus restated a “buy” rating and set a $69.00 target price (up previously from $60.00) on shares of Zoetis in a report on Tuesday, May 30th. Finally, CL King started coverage on Zoetis in a report on Friday, May 26th. They set a “buy” rating and a $71.00 target price for the company. One investment analyst has rated the stock with a sell rating, five have given a hold rating and twelve have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $64.78.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.